Authors
Latest:
Small Cell Transformation: An Increasingly Common Mechanism of Resistance in EGFR-Mutated Lung CancerLung cancer is the main cause of cancer deaths in both men and women in the United States. The disease has 2 major histological subtypes: Non–small cell lung cancer accounts for 85% of cases, with small cell lung cancer comprising the remaining 15%.<sup>1</sup>
Latest:
Novel IDO Inhibitor Yields Durable Responses in Metastatic Pancreatic CancerNovel therapy with indoximod, an indoleamine 2,3-dioxygenase (IDO) pathway inhibitor, in combination with standard chemotherapy, yielded a response rate of 42% as first-line therapy for metastatic pancreatic adenocarcinoma
Latest:
International Symposium on Melanoma May Set Foundations for Clinical Decision MakingOmid Hamid, MD, discusses the upcoming Annual International Symposium on Melanoma and Other Cutaneous Malignancies.
Latest:
Managing HER2+ Early Breast Cancer: Insights and Future HorizonsSandra M. Swain, MD, FACP, FASCO, discusses the potential role for HER2-directed TKIs for the treatment of patients with early-stage HER2+ breast cancer and shares insights about emerging data that could impact the future treatment landscape.
Latest:
Progress With Monoclonal Antibodies in Plasma Cell NeoplasmsSandy Wong, MD, assistant professor, Division of Hematology/Oncology, UCSF School of Medicine, discusses the progress that has been made with monocloncal antibodies for the treatment of plasma cell neoplasms.
Latest:
Overcoming Resistance to Venetoclax in AMLSangmin Lee, MD, discusses a potential way to overcome resistance to venetoclax in acute myeloid leukemia.
Latest:
Combining HDAC Inhibitors With Immunotherapy in MelanomaSanjiv S. Agarwala, MD, chairman of medical oncology at St. Luke’s University Health Network, discusses the combination of immunotherapy and a histone deacetylase inhibitor in patients with melanoma, as well as other types of cancer.
Latest:
Dr. Sant P. Chawla on Trabectedin for the Treatment of Mesenchymal ChondrosarcomaSant P. Chawla, MD, director, Sarcoma Oncology Center, discusses the potential for trabectedin as treatment of mesenchymal chondrosarcoma.
Latest:
Unanswered Questions in the HER2+ Breast Cancer SpaceSara A. Hurvitz, MD, discusses some of the current important questions for the field of HER2-positive breast cancer now and highlights which of these unanswered questions she hopes are addressed soon.
Latest:
Rusfertide Lowers Hematocrit in Patients With Polcythemia VeraWith rusfertide, clinical trial investigators are poised to fill a clinical gap by addressing iron deficiency in patients with polycythemia vera.
Latest:
Emerging Treatment Approaches in HER2+ Breast CancerBefore closing out their discussion on HER2+ breast cancer, expert oncologists share excitement for emerging treatment strategies and ongoing clinical trials.
Latest:
Overview of TROPiCS-02 Study of Sacituzumab Govitecan in HR+/HER2- mBCSara Tolaney, MD, MPH, discusses sacituzumab govitecan-hziy as an effective and safe treatment for patients with hormone receptor-positive/HER2-negative metastatic breast cancer.
Latest:
Considering the Role of Clinical Trials for Patients With Molecularly Altered Lung CancersSarah B. Goldberg, MD, MPH, discusses the role of clinical trials in patients with lung cancer who have molecularly altered tumors, such as <em>EGFR</em>, <em>ALK</em>, <em>BRAF</em>,<em>ROS1, </em>or other alterations. These patients typically consider either targeted therapy or immunotherapy treatment options.
Latest:
Next Generation Diagnostics for Immuno-OncologyUnlike traditional diagnostics that measure the presence, absence, or altered levels of a single analyte, immuno-oncology diagnostics seek to coalesce large amounts of immunological and tumor information into "signatures" that can be used to guide patient care.
Latest:
Expert Reviews Study Findings for Radical Hysterectomy in Cervical CancerSarah Ferguson, MD, FRCSC, discusses her experience being involved in a population-based study of women with cervical cancer treated with a radical hysterectomy.
Latest:
Dr. Sarah Goldberg on Further Immunotherapy Trials in Non-Small Cell Lung CancerSarah Goldberg, MD, MPH, assistant professor of Medicine and Medical Oncology, Yale Cancer Center, discusses coming trials looking at immunotherapy beyond the second-line setting in non-small cell lung cancer (NSCLC).
Latest:
Quadruplet Versus Triplet Regimens in Multiple MyelomaSarah Holstein, MD, PhD, explains her rationale for choosing a triplet regimen over a quadruplet in patients with multiple myeloma.
Latest:
Areas Under Investigation in Ph-Like ALLSarah K. Tasian, MD, discusses what she finds most interesting about Philadelphia chromosome (Ph-like) acute lymphoblastic leukemia.
Latest:
Telemedicine Improves Accessibility of CAR T-Cell TherapySarah Murawski, MPAS, discusses how telemedicine can impact the use of chimeric antigen receptor T-cell therapy in patients with cancer at the Association of Community Cancer Centers National Oncology Conference.
Latest:
Amcenestrant’s Potential Role in ER+/HER2- Metastatic Breast CancerSarat Chandarlapaty, MD, offers his opinion on the potential roles amcenestrant could have in the treatment of ER+/HER2- metastatic breast cancer.
Latest:
Key Takeaway From 2-Year Follow-Up Data of ZUMA-1 Trial in Large B-Cell LymphomaSattva S. Neelapu, MD, discusses the main takeaway from 2-year follow-up data from the ZUMA-1 trial looking at axicabtagene ciloleucel in patients with refractory large B-cell lymphoma.
Latest:
Dr. Eggener Discusses Racial Disparities in Prostate CancerScott Eggener, MD, associate professor of surgery, co-director, Prostate Cancer Program, director, Transitional and Outcomes Research, Section of Urology, The University of Chicago Medicine, discusses racial disparities in men with prostate cancer.
Latest:
Surgical Choices for Multifocal Lung CancerScott J. Swanson, MD, co-director of Minimally Invasive Surgery and chief surgical officer at Brigham and Women’s Hospital, professor of Surgery at Harvard Medical School, discusses surgical choices for patients with multifocal lung cancer.
Latest:
KISIMA-01 Investigates the Safety of ATP128 With or Without Ezabenlimab in CRCScott Kopetz, MD, PhD, FACP, explains the purpose of the phase 1b KISIMA-01 study of the ATP128 vaccine used with or without with or without ezabenlimab to treat patients with advanced colorectal cancer.
Latest:
Updated Survival Data from BEACON CRC Lead to More Specific QuestionsScott Kopetz, MD, PhD, discusses the next steps following the phase 3 BEACON CRC trial of encorafenib plus cetuximab with or without binimetinib compared with irinotecan or FOLFIRI plus cetuximab in patients with BRAF V600E metastatic colorectal cancer.
Latest:
AP128 Vaccine Shows Preliminary Safety in Stage IV CRCScott Kopetz, MD, PhD, FACP, reviews the results of the phase 1b multicenter KISIMA-01 study, for which he presented preliminary results during the ESMO World Congress of Gastrointestinal Cancer 2021.
Latest:
An Overview of the St. Jude Cloud Data-Sharing ResourceScott Newman, PhD, St. Jude Children’s Research Hospital, discusses the St. Jude Cloud data-sharing resource for the research community.
